Entrada Therapeutics (TRDA) Change in Account Payables (2020 - 2026)

Entrada Therapeutics' Change in Account Payables history runs 7 years deep, the most recent figure standing at $641000.0 for Q1 2026.

• In Q1 2026, Change in Account Payables rose 133.56% year-over-year to $641000.0; the TTM figure through Mar 2026 stood at $752000.0 (up 384.85% YoY), while the FY2025 annual figure was -$1.8 million, down 281.53% from the prior year.
• Change in Account Payables for Q1 2026 stood at $641000.0, up from -$877000.0 in the prior quarter.
• The five-year high for Change in Account Payables was $4.6 million in Q4 2022, with the low at -$4.4 million in Q2 2023.
• The 5-year median for Change in Account Payables is -$314000.0 (2024), against an average of $136176.5.
• Peak annual rise in Change in Account Payables reached 869.03% in 2022, while the deepest fall reached 3733.75% in 2022.
• Entrada Therapeutics' Change in Account Payables stood at $4.6 million in 2022, then tumbled by 47.62% to $2.4 million in 2023, then gained by 18.29% to $2.8 million in 2024, then tumbled by 130.82% to -$877000.0 in 2025, then surged by 173.09% to $641000.0 in 2026.
• Business Quant data shows TRDA's Change in Account Payables at $641000.0 in Q1 2026, -$877000.0 in Q4 2025, and $1.3 million in Q3 2025.